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Abstract
Background: Infections due to Respiratory Syncytial Virus (RSV) and Influenza virus (FLU) are leading causes of
hospitalization in young children. Yet, there is little data on factors associated with antibiotic use in these patients.
Methods: We conducted a retrospective, single-center study of all patients below 2 years of age hospitalized
between 2014 and 2018. We compared children with RSV infection to children with FLU infection analyzing clinical
characteristics and factors contributing to an increased rate of antimicrobial utilization.
Results: RSV infection was diagnosed in 476/573 (83.1%), FLU in 95/573 (16.6%), and RSV-FLU-co-infection in 2/573
(0.3%) patients. Median age was lower for RSV compared to FLU (4 vs. 12 months; p < 0.0001). Children with RSV
had longer hospitalization (5 vs. 4 days; p = 0.0023) and needed oxygen more frequently (314/476 vs. 23/95; p <
0.0001) than FLU patients. There was no significant difference in the overall antibiotic utilization between RSV and
FLU patients (136/476 vs. 21/95; p = 0.2107). Logistic regression analyses revealed that septic appearance on
admission (odds ratio [OR] 8.95, 95% confidence interval [CI] 1.5–54.1), acute otitis media (OR 4.5, 95% CI 2.1–9.4), a
longer oxygen therapy (OR 1.40; 95% CI 1.13–1.74) and a higher C-reactive protein (CRP) (OR 1.7, 95% CI 1.5–2.0)
were significantly associated with antibiotic use in both groups, but not age or pneumonia.
Conclusions: In our cohort, the rate of antibiotic utilization was comparable between RSV and FLU patients, while
for both groups distinct clinical presentation and a high CRP value were associated with higher antibiotic use.
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Background
Respiratory tract infections (RTI) are the most common
diagnoses in children, especially below the age of 2 years
[1]. They substantially contribute to morbidity and mor-
tality worldwide [2]. Furthermore, RTI are associated
with large societal impacts [3], including a high health-
economic burden [4], caused by a high hospitalization
rate among the very young, causing frequent parental
absence from work [5]. Moreover, antimicrobial con-
sumption is heavily driven by RTI [6] due to the clinical
challenge of distinguishing between viral and bacterial
etiologies and the lack of a reliable diagnostic reference
standard [7, 8]. Antimicrobial stewardship (AMS) pro-
grams are increasingly implemented [9] to counteract
this antibiotic overuse which is strongly associated with
the upsurge in antimicrobial resistance [10],
The respiratory syncytial virus (RSV) and the Influenza
virus (FLU) account for the majority of RTI in infants
leading to hospitalization [11, 12]. With the advent of
novel point-of-care tests based on nucleic acid amplifica-
tion, diagnostic accuracy and turnaround time of results
have dramatically increased over the past years, both for
RSV and FLU [13, 14]. Yet, there is only limited data in-
dicating the potential clinical benefit of rapid viral test-
ing as a tool of AMS in the hospital setting [15]. The
overall quality of evidence was generally regarded low,
making only for a “weak recommendation” in the latest
Guidelines by the Infectious Diseases Society of America
and the Society for Healthcare Epidemiology of America
for implementing an AMS program [16].
In a recent systematic review with meta-analysis, in-
cluding both diagnostic accuracy studies and clinical im-
pact studies, no firm conclusion could be made on the
clinical impact of viral testing on antibiotic use due to
the heterogeneity of the included studies [17], of which
only two had included children.
Little is known about the factors that influence anti-
biotic prescription in patients with a positive RSV or
FLU test. We sought to analyze the rate of antibiotic use
in RSV and FLU patients and associated clinical and la-
boratory factors.
Methods
Study setting and design
This retrospective, single-center analysis was conducted at
the University Children’s Hospital Mannheim, Medical
Faculty Mannheim of the Heidelberg University,
Germany. The local ethics committee approved of the
study (2018-832R-MA). All patients below 2 years of age
hospitalized for RSV or FLU infection between the April
2014 and April 2018 were included, thereby covering 4
complete epidemic seasons. Patients were identified by a
hospital database search for the corresponding ICD-10
codes (J12.1, J21.0, J20.5, B97.4; J09-J11.-) as the primary
diagnosis and, to avoid selection bias, also as secondary
diagnosis. RSV or FLU infection were each defined as a
positive result from a nasopharyngeal swab either in a
rapid point-of-care test (Sofia® Influenza A + B Fluorescent
Immunoassay and Sofia® RSV Fluorescent Immunoassay;
Quidel, San Diego, California, USA) or in a multiplex PCR
(Biofire® Filmarray® Respiratory Panel, Biomérieux, Marcy-
l’Étoile, France), which comprises adenovirus; corona-
viruses 229E, HKU1, OC43, and NL63; human metapneu-
movirus; human rhinovirus/enterovirus; influenza A
(including substrains) and B; parainfluenza viruses 1 to 4;
RSV; Bordetella pertussis; Chlamydophila pneumoniae;
and Mycoplasma pneumoniae.
Chart review included present and past medical his-
tory, family history, preexisting antibiotic therapy, clin-
ical findings, results of laboratory, microbiological and
radiological investigations, data on therapy, need for
oxygen, intensive care, and length of stay. Clinical ap-
pearance was defined as documented as the physical
examination upon admission, including “well”, “ill”, and
“septic” appearance. The clinical syndrome was defined
according to the discharge diagnosis and/or the docu-
mented clinical symptoms on admission, as either upper
respiratory tract infection (URTI), bronchitis/bronchio-
litis, pneumonia, or fever of unknown origin (FUO).
Case numbers were compared between the seasons to
check for imbalances.
We compared children with RSV infection to children
with FLU infection. Especially, clinical characteristics and
factors contributing to an increased rate of antimicrobial
utilization were analysed of RSV and FLU infected chil-
dren. Furthermore, we defined subgroups of children
within each group and compared those treated with anti-
biotics (RSV+AB+; FLU+AB+) to those who were not
treated with antibiotics (RSV+AB-; FLU+AB-), respect-
ively. Antibiotic utilization was defined as any given dose
during the hospital stay. We assessed antibiotic therapy in
terms of substance and length of therapy.
Statistical analysis
Statistical analyses were performed in SAS (Statistical
Analysis System, North Carolina, USA). Mann-Whitney
U test was used for group comparison between RSV and
FLU. For multiple comparisons, Kruskal-Wallis test and
one-way analysis of variance were applied. Logistic re-




Overall, 573 children were eligible for analysis, with a me-
dian age of 5months (IQR 2–11) and a male predomin-
ance of 325/573 (56.7%). Of the 573 children, 476 were
identified as having RSV infection (83.1%), and 95 as
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having FLU infection (16.6%), while in two patients, RSV-
FLU co-infection was detected (0.3%). RSV patients were
significantly younger than FLU patients (4 vs. 12months;
p < 0.0001) (Table 1), while 19.5% of RSV patients were
28 days of age or younger and 47.7% 3 months of age or
younger. The majority of RSV patients presented during
the months January and February (32.4 and 25.4%), while
FLU patients were predominantly diagnosed in February
and March (43.2 and 25.3%) (Fig. 1).
Seasonality
We assessed the seasonal variability (Fig. 1). Numbers
were comparable between the seasons except for one
season each with a higher burden of RSV (2016/2017)
and FLU (2017/2018).
Baseline risk factors
We assessed patients with respect to a positive past
medical history with focus on prematurity, congenital
heart disease, congenital diaphragmatic hernia, trisomy
21, and recurrent episodes of bronchitis, but could not
find any significant differences, although prematurity
and recurrent bronchitis were slightly more common in
RSV (4.4 and 4.8%, respectively) than in FLU patients
(2.1 and 3.1%, respectively), both missing statistical sig-
nificance. Furthermore, similar sick contacts were
Table 1 Comparison of clincial and laboratory characteristics of RSV and FLU patients; median and interquartile range are indicated
for continuous variables; ns not significant
Variables RSV FLU p-values
N (%) 476 (83.1%) 95 (16.6%)
Male 269/476 (56.5%) 55/95 (57.9%) ns
Age, months 4 (2–8) 12 (5.5–18) < 0.0001
Duration of illness, days 4 (2–5) 3 (2–5) 0.0005
Fever (≥38.0 °C) 330/476 (69.3%) 93/95 (97.9%) < 0.0001
Body temperature on admission, °C 37.5 (37.1–38.3) 38.4 (37.5–39.3) < 0.0001
Peak body temperature, °C 38.7 (37.7–39.4) 39.9 (39.1–40.1) < 0.0001
Oxygen saturation at admission, % 97 (94–98) 98 (96–100) 0.0002
Minimal oxygen saturation, % 90 (88–94) 96 (90–98) < 0.0001
Need for intensive care 16/476 (3.4%) 1/95 (1.1%) ns
Length of stay, days 5 (4–7) 4 (3–6.5) 0.0023
Blood culture obtained 165/476 (34.7%) 54/95 (56.8%) < 0.0001
CRP on admission, mg/L 6.9 (0–17.6) 6.6 (0–14.1) ns
Peak CRP, mg/L 12.3 (5.8–29.2) 11.7 (5.4–23.7) ns
WBC on admission, 10^9/L 10.7 (8.5–13.2) 10.8 (7.1–13.6) ns
Chest radiography performed 135/476 (28.4%) 18/95 (18.9%) ns
Infiltrate on chest radiogram 72/135 (53.3%) 13/18 (72.2%) ns
Preexisting antibiotic therapy 32/476 (6.7%) 14/95 (14.7%) 0.0188
Well appearance 32/476 (6.7%) 6/95 (6.3%) ns
Ill appearance 245/476 (51.5%) 62/95 (65.3%) 0.0176
Septic appearance 168/476 (35.3%) 23/95 (24.2%) 0.0426
Febrile seizure 3/476 (0.6%) 14/95 (14.7%) < 0.0001
Acute otitis media 70/476 (14.7%) 33/95 (34.7%) < 0.0001
Upper respiratory tract infection 0/476 (0%) 47/95 (49.5%) < 0.0001
Bronchitis/Bronchiolitis 236/476 (49.6%) 6/95 (6.3%) < 0.0001
Pneumonia 239/476 (50.2%) 21/95 (22.1%) < 0.0001
Fever of unknown origin 1/476 (0.2%) 21/95 (22.1%) < 0.0001
Death 0/476 1/95 (1.1%) ns
Oxygen therapy 314/476 (66.0%) 23/95 (24.2%) < 0.0001
Length of oxygen therapy, days 2 (0–5) 0 < 0.0001
Antibiotic therapy 136/476 (28.6%) 21/95 (22.1%) 0.2107
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observed for 38.9% of RSV and for 45.3% of FLU pa-
tients (statistically not significant).
Clinical presentation, treatment and outcome of RSV and
FLU patients
Both patient groups presented with similar durations of
illness, but a significant number of FLU patients had re-
ceived antibiotics before presenting to the hospital
(14.7% vs. 6.7%; p = 0.0188). The clinical syndrome diag-
nosed upon admission was lower respiratory tract infec-
tion (49.6%) or pneumonia (50.2%) for most of the RSV
patients (compared to 6.3% und 22.1% for FLU patients,
respectively; both p < 0.0001), while in FLU patients,
upper respiratory tract infections (49.5%) and FUO
(22.1%) accounted for the majority of clinical manifesta-
tions (compared to 0.2 and 0% for RSV patients, respect-
ively; both p < 0.0001). In association with this, fever,
and also febrile convulsions were significantly more
often found in FLU patients (Table 1). Acute otitis
media was significantly more often diagnosed among
FLU patients (p < 0.0001).
RSV patients needed significantly more often oxygen
therapy (66% vs. 24.2%; p < 0.0001) and salbutamol
(68.3% vs. 27.1%; p < 0.0001) than FLU patients, and had
longer hospital stays (5 vs. 4 days; p = 0.0023), while
there were no statistically significant differences con-
cerning the need for intensive care and antibiotic ther-
apy. One FLU patient died due to severe pneumonia
with suspected bacterial co-infection, leading to respira-
tory failure.
Laboratory, microbiological and radiological findings in
RSV and FLU patients
No significant differences were found between both
groups concerning C-reactive protein (CRP) and white
blood cell counts (WBC). Chest radiographs were per-
formed slightly more often in RSV patients (28.4% vs.
19.8%; not significant), while infiltrates were slightly more
frequently diagnosed among FLU patients (72.2% vs.
53.3%; not significant).
For 19 patients, a multiplex PCR on a nasopharyngeal
swab was available (14 RSV patients, 5 FLU patients).
Among the 14 patients with RSV infection for whom a
multiplex PCR was available, adenovirus was concomi-
tantly detected in two patients and coronavirus and Borde-
tella pertussis in one patient, each. In FLU patients,
adenovirus and human metapneumovirus were detected
in one patient, each. Blood cultures were ordered in 165
patients with RSV, of whom 9 were positive, all of which
were deemed contaminants (5 coagulase negative
staphylococci; 1 co-detection of Staphylococcus epidermi-
dis, Streptococcus mitis, and Streptococcus peroris; 1 co-
detection of Micrococcus luteus and Pseudomonas stutzeri;
1 Micrococcus luteus; 1 Rothia dentocariosa). For FLU pa-
tients, blood cultures were ordered in 54, with 3 positive
cultures, all regarded as contamination (2 Staphylococcus
hominis; 1 Corynebacterium afermentans).
Antibiotic utilization
Antibiotics were prescribed in 136/476 (28.6%) of RSV
patients and 21/95 (22.1%) of FLU patients (p = 0.2107).
A monotherapy was used in 77/136 (56.6%) in RSV pa-
tients and 15/21 (71.4%) of FLU patients (p = 0.2395),
while the remaining fractions were prescribed a combin-
ation therapy. For RSV patients, the most frequently or-
dered therapies were aminopenicillin monotherapy in
44/136 (32.4%), ampicillin + flucloxacillin combination
therapy in 41/136 (30.1%), and ampicillin + gentamicin
combination therapy in 17/136 (12.5%). For FLU pa-
tients, ampicillin/sulbactam was prescribed in 7/21
(33.3%), followed by an aminopenicillin monotherapy in
4/21 (19.0%) and ampicillin + flucloxacillin combination
therapy in 4/21 (19.0%). The distribution of prescribed
antibiotics is depicted in Fig. 2. The median length of
antibiotic therapy was 5.5 days for RSV patients (IQR 4–
7) and 6 days for FLU patients (IQR 4–8) (p = 0.3680).
Fig. 1 Distribution of cases for each month for RSV (blue) and FLU (orange)
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Subgroup comparison – RSV patients
We compared RSV patients who received antibiotics
(RSV+AB+) during the hospital stay to those without an-
tibiotics (RSV+AB-). Children who were RSV+AB+ were
significantly older than RSV+AB- (6 vs. 3 months; p =
0.0025) (Table 2). Furthermore, they presented signifi-
cantly more often with fever (91.2% vs. 60.6%; p <
0.0001), a septic appearance (48.5% vs. 30%; p = 0.0002),
pneumonia (76.8% vs. 39.1%; p < 0.0001), acute otitis
media (26.5% vs. 10%; p < 0.0001), and a higher CRP on
admission (26.9 mg/L vs. 4.3 mg/L; p < 0.0001). During
the hospital stay, RSV + AB+ children had significantly
higher rates of chest radiographies (60.3% vs. 15.6%; p <
0.0001), blood cultures obtained (52.2% vs. 27.6%; p <
0.0001), oxygen therapy (80.1% vs. 60%; p < 0.0001), in-
tensive care stays (9.6% vs. 0.9%; p < 0.0001), and longer
hospital stays in total (6 days vs. 5 days; p < 0.0001).
Subgroup comparison – FLU patients
For FLU patients, a significant difference upon clinical
presentation was a higher rate of pneumonia (52.4% vs.
13.5%; p = 0.0005) and acute otitis media (57.1% vs.
28.4%; p = 0.0199) among children receiving antibiotics
(FLU+AB+) compared to children without antibiotics
(FLU+AB-) (Table 2). Apart from that, FLU+AB+ chil-
dren had significantly higher CRP on admission (23.1
mg/L vs. 4.9 mg/L; p < 0.0001) and peak CRP (54.9 mg/L
vs. 9.4 mg/L; p < 0.0001) in the course of disease; a
higher rate of chest radiography performed (52.4% vs.
9.5%; p < 0.0001), higher need for oxygen therapy (57.1%
vs. 14.9%; p = 0.0002), and a longer hospital stay (6 days
vs. 5 days; p = 0.0003).
Risk factors for antibiotic use
We performed a multivariate logistic regression to iden-
tify risk factors associated with antibiotic utilization
among both RSV and FLU. The best model fit for anti-
biotic use at any time point was achieved for the follow-
ing factors (c-index 0.916) (Table 3): otitis media (odds
ratio 8.33; 95% confidence interval 3.58–19.37), peak
CRP (OR 1.77; 95% CI 1.54–2.04), and the length of oxy-
gen therapy (OR 1.40; 95% CI 1.13–1.74). Septic
Fig. 2 Distribution of empiric antibiotics prescribed after hospitalization, absolute numbers; a RSV patients (N = 136); b influenza patients (N = 21);
gen.: generation
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appearance (OR 4.882; 95% CI 0.866–27.505; p = 0.0723)
was statistically not significant.
The best model fit for antibiotic use on admission (c-
index 0.896) (Table 4) was achieved for otitis media (OR
4.5, 95% CI 2.1–9.4), CRP on admission (OR 1.7, 95% CI
1.5–2.0), and septic appearance (OR 8.95, 95% CI 1.5–
54.1). Pneumonia as a potential risk factor (OR 3.629,
95% CI 0.902–14.602) missed statistical significance.
Discussion
In this large retrospective four-season-analysis we
present data on more than 570 children below the age of
2 years with RSV or FLU infection, demonstrating a high
antibiotic use in a substantial proportion of children.
Recent systematic reviews with meta-analyses had
shown that viral testing, including FLU and RSV, does
not affect antibiotic prescription rates [17, 18],
Table 2 Comparison of clincial and laboratory characteristics of RSV and FLU patients receiving antibiotics (AB+) to those not










N (%) 136/476 (28.6%) 340/476 (71.4%) 21/95 (22.1%) 74/95 (77.9%)
Male 76/136 (55.1%) 193/340 (56.8%) ns 11/21 (52.4%) 44/74 (59.5%) ns
Age, months 6 (2–12) 3 (2–7) 0.0025 14 (9–18) 11 (5–17.8) ns
Duration of illness, days 4 (2–5) 3 (2–5) ns 3 (2–5.3) 2 (2–4) ns
Fever (≥38.0 °C) 124/136 (91.2%) 206/340 (60.6%) < 0.0001 20/21 (95.2%) 73/74 (98.6%) ns
Body temperature on admission, °C 38.0 (37.4–38.8) 37.4 (37.0–38.1) < 0.0001 38.2 (37.7–39-4) 38.4 (37.4–39.3) ns
Peak body temperature, °C 39.2 (38.8–39.8) 38.2 (37.5–39.2) < 0.0001 40.0 (39.4–40.1) 39.8 (39.1–40.0) ns
Oxygen saturation at admission, % 96 (93–98) 97 (95–98) 0.0019 97 (93.3–98.3) 98 (97–100) ns
Minimal oxygen saturation, % 89 (88–92) 91 (88–95) < 0.0001 90 (87.8–95.3) 96 (95–98) ns
Need for intensive care 13/136 (9.6%) 3/340 (0.9%) < 0.0001 1/21 (4.8%) 0/74 ns
Length of stay, days 6 (5–8.3) 5 (3–7) < 0.0001 6 (5–8.5) 5 (3–7) 0.0003
Blood culture obtained 71/136 (52.2%) 94/340 (27.6%) < 0.0001 12/21 (57.1%) 42/74 (56.8%) ns
CRP on admission, mg/L 26.9 (9.7–51.2) 4.3 (0–10.6) < 0.0001 23.1 (5.9–58.4) 4.9 (0–13.0) < 0.0001
Peak CRP, mg/L 40.5 (19.2–61.5) 7.9 (4.5–14.4) < 0.0001 54.9 (11.7–76.8) 9.4 (4.2–14.2) < 0.0001
WBC on admission, 109/L 11.6 (8.5–15.2) 10.5 (8.5–12.7) ns 9.9 (7.6–12.0) 10.9 (7.1–13.7) ns
Chest radiography performed 82/136 (60.3%) 53/340 (15.6%) < 0.0001 11/21 (52.4%) 7/74 (9.5%) < 0.0001
Infiltrate on chest radiogram 48/82 (58.5%) 24/53 (45.3%) ns 8/11 (72.7%) 5/7 (71.4%) ns
Preexisting antibiotic therapy 19/136 (14.0%) 13/340 (3.8%) 0.0002 6/21 (13.7%) 8/74 (3.9%) ns
Well appearance 1/136 (0.7%) 31/340 (9.1%) 0.0004 2/21 (9.5%) 4/74 (5.4%) ns
Ill appearance 60/136 (44.1%) 185/340 (54.4%) 0.0536 12/21 (57.1%) 50/74 (67.6%) ns
Septic appearance 66/136 (48.5%) 102/340 (30%) 0.0002 6/21 (28.6%) 17/74 (23.0%) ns
Acute otitis media 36/136 (26.5%) 34/340 (10%) < 0.0001 12/21 (57.1%) 21/74 (28.4%) 0.0199
Upper respiratory tract infection 0/136 (0%) 0/340 (0%) ns 5/21 (23.8%) 42/74 (56.8%) 0.0123
Bronchitis/Bronchiolitis 31/136 (22.5%) 207/340 (60.9%) < 0.0001 1/21 (4.8%) 5/74 (6.8%) ns
Pneumonia 106/136 (76.8%) 133/340 (39.1%) < 0.0001 11/21 (52.4%) 10/74 (13.5%) 0.0005
Fever of unknown origin 0/136 (0%) 0/340 (0%) ns 4/21 (19.0%) 17/74 (23.0%) ns
Oxygen therapy 109/136 (80.1%) 204/340 (60%) < 0.0001 12/21 (57.1%) 11/74 (14.9%) 0.0002
Length of oxygen therapy, days 3 (2–6) 2 (0–4) < 0.0001 1 (0–6) 0 0.0002
Table 3 Logistic regression model for antibiotic use at any time point
Variables Odds ratio 95% confidence interval p-value
Otitis media 8.325 3.577–19.374 < 0.0001
Peak CRP 1.772 1.538–2.041 < 0.0001
Length of oxygen therapy 1.404 1.130–1.744 0.0022
Septic appearance 4.882 0.866–27.505 0.0723
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indicating that other factors pertaining to the
decision-making of physicians need to be addressed
by AMS measures.
Although RSV patients were significantly younger in
our cohort, this apparently did not contribute to a
higher rate of antibiotic utilization, as RSV children with
antibiotics were significantly older than RSV children
that did not receive antibiotics. Instead, driving factors
for a potential antibiotic overuse were a high CRP, the
presence of acute otitis media, septic appearance and the
length of oxygen therapy.
FLU patients presented significantly more often with
fever, febrile convulsions, acute otitis media, and upper
respiratory tract infection or fever of unknown origin,
while RSV patients presented significantly more often
with a lower oxygen saturation, septic appearance, and
lower respiratory tract infection or pneumonia.
We found higher rates of blood cultures obtained from
FLU patients than from RSV patients, which in large
part can be explained by the higher rate of febrile chil-
dren in the FLU cohort, while chest radiographies were
more frequently performed among those who received
antibiotics within both groups. Interestingly, we found
rates of chest infiltrates comparable between treated and
non-treated patient groups. One possible explanation is
that performing a chest radiograph serves as a surrogate
for disease severity and hence influences the decision to
prescribe antibiotics. In previous studies, it was hy-
pothesized that less specific radiologic findings may
have pushed physicians towards antibiotic treatment,
even in the absence of infiltrates [19]. Still, it is gen-
erally advised against routinely performing chest ra-
diographs in children who present with typical
clinical findings of viral bronchiolitis, of which the
majority is caused by RSV [20].
Male children were more predominant in both RSV
and FLU cohorts, which had been reported similarly in
previous studies [21], yet without convincing explana-
tions so far [22]. Of note, the rate of antibiotic use be-
fore admission was 2.2 times higher among FLU
patients, while during hospitalization, more RSV patients
received antibiotics.
The antibiotic utilization in 28.6% of RSV and 22.1%
of FLU patients respectively is lower than in comparable
cohorts published in the recent past [23, 24], which may
reflect a stronger reluctance to use antibiotics in chil-
dren with point-of-care test confirmed viral infections at
our hospital.
Complex medical comorbidities, such as chronic lung
disease due to prematurity and congenital heart disease,
are known risk factors for hospitalization due to RSV in-
fection [25, 26]. In our cohort, we did not find any dif-
ference in these comorbidities between RSV and FLU
patients.
The strengths of our study are the study size, allowing
for robust statistical analyses, the long inclusion period,
accounting for fluctuations of virus seasonality, and the
consistency in standard of care during the inclusion
period, thereby avoiding unwanted biasing effects.
Certain limitations of the study also merit critical ap-
praisal. First, we obtained data retrospectively, bringing
about the usual constraints and biases inherent to the
nature of retrospective analyses. As such, we could not
assess the effect of vaccination coverage, especially per-
taining to influenza, on the study outcomes since these
data were not systematically obtained. In Germany, cur-
rently no general recommendation for FLU vaccination
for children exists, but only for those with chronic med-
ical conditions. Secondly, no reference method was ap-
plied with regard to the correctness of antibiotic
utilization. The correct judgement whether an antibiotic
is warranted or not is hindered by the lack of a reference
standard. Several methods exist to account for this, e.g. a
panel of expert referees, blinded to each other, reviewing
each case and adjudicating on the “correct” etiology, i.e.
bacterial, viral, bacterial-viral co-infection, or unknown,
as applied in other studies [21, 27]. Third, our cohort
lacked an additional systematic viral testing beyond RSV
and Influenza for all patients, making it impossible to
judge whether other viruses, such as adenovirus, may
have played a causative role, especially in cases with
higher CRP [28]. Other viruses, albeit rarer, such as the
human metapneumovirus, can be equally or even more
associated with antibiotic overuse in children, as de-
scribed by Schreiner and colleagues [29]. An extensive
pathogen testing in conjunction with a control group of
healthy children may have helped to better appraise the
role of other viruses or bacteria, since some microorgan-
isms can be found abundantly also in healthy controls
[11], and the co-presence of some pathogens have been
reported to correlate with disease severity [30]. Of note,
O’Grady and colleagues had found that more than half
of children with an acute respiratory infection had a
viral-bacterial “co-detection” in nasal swabs, the bacter-
ium in most cases being Haemophilus influenzae [31]. In
another study in children with lower respiratory tract in-
fections [32], the most common detected potentially
pathogenic colonizers were Haemophilus influenzae
(32.1%), Moraxella catharralis (26.7%), Staphylococcus
Table 4 Logistic regression model for antibiotic use on
admission
Variable Odds ratio 95% confidence interval p-value
Otitis media 4.496 2.141–9.439 < 0.0001
CRP on admission 1.687 1.457–1.953 < 0.0001
Septic appearance 8.950 1.481–54.087 0.0169
Pneumonia 3.629 0.902–14.602 0.0696
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aureus (17.7%) and Streptococcus pneumoniae (16.7%).
Nevertheless, detection of bacterial colonizers may not
help in the decision to initiate antibiotic therapy. In-
stead, there is evidence that the utilization of viral point-
of-care diagnostics may prevent the usage of antibiotics
[33, 34]. Overall, this fits well into the concept of diag-
nostic as well as antibiotic stewardship. Fourth, our co-
hort had a low case fatality rate, which reduces
comparability to cohorts from other backgrounds, e.g.
from low- and middle-income countries, where mortality
may be higher [35]. Finally, the low baseline rate of anti-
biotic utilization may limit the generalizability of our re-
sults to other settings where the culture of prescribing
antibiotics especially in infants and young children
below the age of 2 years may differ [36] due to a lack of
AMS or other reasons.
In light of the imperfection of both clinical features [7]
and laboratory parameters such as CRP [37, 38], novel
diagnostics measures are needed to better distinguish
between viral and bacterial infections and thereby help
reducing unwarranted antibiotic therapy. New host-
protein based assays, e.g. combining CRP with Myxo-
virus resistance protein A [39], but also combinations of
CRP and tumor-necrosis-factor related apoptosis
inducing ligand and interferon-gamma induced protein
10, have shown very convincing results in studies [21,
40–42], with high diagnostic accuracy and a potential to
dampen unnecessary antibiotic use. Transcriptomic sig-
natures have also shown to be very accurate in establish-
ing the true etiology [43, 44], and although cost issues
and turnaround times steadily improve [45], practical
feasibility and implementation into the clinical workflow
are persisting challenges still to be taken.
Conclusions
In summary, we show that clinical appearance on admis-
sion, the presence of otitis media, but also a high CRP
and the length of oxygen therapy are the main factors
associated with antibiotic use in our cohort of in chil-
dren below the age of 2 years with RSV or FLU infection.
It remains to be proven in prospective studies if AMS
interventions aiming at viral testing, e.g. as multiplex
PCR, in conjunction with more precise biomarkers or
combinations thereof can help to effectively reduce anti-
biotic treatment in children with RSV infection and
Influenza.
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